John McKearn
Voorzitter bij Arch Oncology, Inc.
Vermogen: 135 199 $ op 31-05-2024
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| John Mulligan | M | - |
Good Therapeutics, Inc.
 Good Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Good Therapeutics, Inc. operates as a biotechnology company. It develops "context-dependent" protein drugs that sense biomarkers and respond with a therapeutic activity. The company was founded by John Mulligan in 2016 and is headquartered in Seattle, WA.
Bonum Therapeutics, Inc.
 Bonum Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bonum Therapeutics, Inc. is a privately held American company that focuses on generating a new class of therapeutics based on a proven technology platform. Bonum Therapeutics is based in an undisclosed location and was founded in 2022 by the Good Therapeutics team. The company's technology utilizes principles of allosteric regulation to create highly active and less toxic medicines, which can be applied to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company's molecules combine a sensor component directed against a specific biological marker and a therapeutic component. The company is backed by a group of leading venture investors, including Codon Capital, Roche Venture Fund, RiverVest Venture Partners, 3x5 Partners, Digitalis Ventures, and Vivo Capital. The company was founded by John Mulligan, who has been the CEO since incorporation. | 8 jaar |
| Robert Southworth Searle | M | - |
Searle & Co., Inc.
 Searle & Co., Inc. Investment ManagersFinance Searle & Co., Inc. provides investment advisory services. The business continuity plan addresses data back up and recovery, all mission critical systems, financial and operational assessments, alternative communications with customers, employees, regulators, alternate physical location of employees, critical supplier, contractor, bank and counter-party impact, regulatory reporting and assuring their customers prompt access to their funds and securities if they are unable to continue their business. The company was founded in 1982 and is headquartered in Greenwich, CT | 22 jaar |
| Adam Tomasi | M | 54 | 7 jaar | |
| Daniel Janney | M | 58 | 7 jaar | |
| Clifford Stocks | M | - |
OncoResponse, Inc.
 OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | 9 jaar |
| Laurence J. Blumberg | M | 62 |
Arch Oncology, Inc.
 Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | 3 jaar |
| Robert Alexander | M | 54 | 7 jaar | |
| Poppy Keller | F | - |
RiverVest Venture Management LLC
 RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri with additional offices in San Diego and Cleveland. | 19 jaar |
| Natalie Mount | M | - |
Wugen, Inc.
 Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | 2 jaar |
| Walter G. Smith | M | - |
OxaluRx, Inc.
| - |
| Kumar Srinivasan | M | 59 |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | 1 jaar |
| Paul Walker | M | 49 | 7 jaar | |
| Ronald Borchardt | M | - |
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri with additional offices in San Diego and Cleveland. | 9 jaar |
| Kelly Cathey | F | - |
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri with additional offices in San Diego and Cleveland. | 24 jaar |
| Niall O'Donnell | M | 51 |
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri with additional offices in San Diego and Cleveland. | 18 jaar |
| Robert Andreatta | M | 62 | 6 jaar | |
| Sean McCarthy | M | 57 |
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | - |
| Michael Berman | M | 66 |
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri with additional offices in San Diego and Cleveland. | 20 jaar |
| Karl D. Handelsman | M | 63 |
Good Therapeutics, Inc.
Good Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Good Therapeutics, Inc. operates as a biotechnology company. It develops "context-dependent" protein drugs that sense biomarkers and respond with a therapeutic activity. The company was founded by John Mulligan in 2016 and is headquartered in Seattle, WA.
Bonum Therapeutics, Inc.
Bonum Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bonum Therapeutics, Inc. is a privately held American company that focuses on generating a new class of therapeutics based on a proven technology platform. Bonum Therapeutics is based in an undisclosed location and was founded in 2022 by the Good Therapeutics team. The company's technology utilizes principles of allosteric regulation to create highly active and less toxic medicines, which can be applied to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company's molecules combine a sensor component directed against a specific biological marker and a therapeutic component. The company is backed by a group of leading venture investors, including Codon Capital, Roche Venture Fund, RiverVest Venture Partners, 3x5 Partners, Digitalis Ventures, and Vivo Capital. The company was founded by John Mulligan, who has been the CEO since incorporation. | - |
| Steven James | M | 66 | 8 jaar | |
| Matthew Cooper | M | - |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | - |
| Isaac Zike | M | - |
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri with additional offices in San Diego and Cleveland. | 5 jaar |
| Jay Schmelter | M | 58 |
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri with additional offices in San Diego and Cleveland. | 24 jaar |
| Tom Melzer | M | - |
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri with additional offices in San Diego and Cleveland. | 24 jaar |
| Pascal Krotee | M | - |
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri with additional offices in San Diego and Cleveland. | 3 jaar |
| Nicholas Walrod | M | - |
Bonum Therapeutics, Inc.
Bonum Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bonum Therapeutics, Inc. is a privately held American company that focuses on generating a new class of therapeutics based on a proven technology platform. Bonum Therapeutics is based in an undisclosed location and was founded in 2022 by the Good Therapeutics team. The company's technology utilizes principles of allosteric regulation to create highly active and less toxic medicines, which can be applied to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company's molecules combine a sensor component directed against a specific biological marker and a therapeutic component. The company is backed by a group of leading venture investors, including Codon Capital, Roche Venture Fund, RiverVest Venture Partners, 3x5 Partners, Digitalis Ventures, and Vivo Capital. The company was founded by John Mulligan, who has been the CEO since incorporation.
Good Therapeutics, Inc.
Good Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Good Therapeutics, Inc. operates as a biotechnology company. It develops "context-dependent" protein drugs that sense biomarkers and respond with a therapeutic activity. The company was founded by John Mulligan in 2016 and is headquartered in Seattle, WA. | 5 jaar |
| Harlan Radford | M | 54 | 3 jaar | |
| Carol Gallagher | M | 59 |
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | - |
| Monique Schiersing | M | - |
Good Therapeutics, Inc.
Good Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Good Therapeutics, Inc. operates as a biotechnology company. It develops "context-dependent" protein drugs that sense biomarkers and respond with a therapeutic activity. The company was founded by John Mulligan in 2016 and is headquartered in Seattle, WA.
Bonum Therapeutics, Inc.
Bonum Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bonum Therapeutics, Inc. is a privately held American company that focuses on generating a new class of therapeutics based on a proven technology platform. Bonum Therapeutics is based in an undisclosed location and was founded in 2022 by the Good Therapeutics team. The company's technology utilizes principles of allosteric regulation to create highly active and less toxic medicines, which can be applied to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company's molecules combine a sensor component directed against a specific biological marker and a therapeutic component. The company is backed by a group of leading venture investors, including Codon Capital, Roche Venture Fund, RiverVest Venture Partners, 3x5 Partners, Digitalis Ventures, and Vivo Capital. The company was founded by John Mulligan, who has been the CEO since incorporation. | - |
| Mark Lewis | M | - |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | - |
| Bobby Sandage | M | 70 |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | - |
| Alex Schwartz | M | - | 3 jaar | |
| Andrew Kleiboeker | M | - |
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri with additional offices in San Diego and Cleveland. | 4 jaar |
| Sivan Weitzman | F | - |
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri with additional offices in San Diego and Cleveland. | 5 jaar |
| Joyce O'Shaughnessy | F | - |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | - |
| Jim Branch | M | - | 13 jaar | |
| Ayman Kabakibi | M | - |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | - |
| Drew Dennison | M | - |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | - |
| Courtney Harris | F | - |
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri with additional offices in San Diego and Cleveland. | 3 jaar |
| Jared Rutter | M | - |
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri with additional offices in San Diego and Cleveland. | 6 jaar |
| Alessandro Sette | M | - |
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri with additional offices in San Diego and Cleveland. | 2 jaar |
| Michel Ducreux | M | - |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | - |
| Mitchell Mutz | M | 61 |
Bonum Therapeutics, Inc.
Bonum Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bonum Therapeutics, Inc. is a privately held American company that focuses on generating a new class of therapeutics based on a proven technology platform. Bonum Therapeutics is based in an undisclosed location and was founded in 2022 by the Good Therapeutics team. The company's technology utilizes principles of allosteric regulation to create highly active and less toxic medicines, which can be applied to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company's molecules combine a sensor component directed against a specific biological marker and a therapeutic component. The company is backed by a group of leading venture investors, including Codon Capital, Roche Venture Fund, RiverVest Venture Partners, 3x5 Partners, Digitalis Ventures, and Vivo Capital. The company was founded by John Mulligan, who has been the CEO since incorporation. | - |
| Curtis Rother | M | - |
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri with additional offices in San Diego and Cleveland. | 7 jaar |
| Joe Biller | M | - |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | - |
| Mark Alles | M | 64 |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | 1 jaar |
| Steven Gillis | M | 71 |
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | - |
| Carole Nüchterlein | F | 62 |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | 8 jaar |
| Wende Hutton | F | 63 |
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | - |
| Kevin Kaijun Li | M | - |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | - |
| Peter Kiener | M | 72 |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | - |
| Bosun Hau | M | 45 |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | - |
| Derek Rapp | M | - |
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri with additional offices in San Diego and Cleveland. | 5 jaar |
| John Dipersio | M | - |
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri with additional offices in San Diego and Cleveland. | 10 jaar |
| Ted Koutouzis | M | - |
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | - |
| Ronald A. Krasnow | M | 61 |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | 4 jaar |
| Karen Spilizewski | F | - |
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri with additional offices in San Diego and Cleveland. | 16 jaar |
| Roberto de Ponti | M | - |
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | 8 jaar |
| Kyle Rasbach | M | - |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | - |
| Walter Smith | M | - |
OxaluRx, Inc.
| 6 jaar |
| Bali Muralidhar | M | 44 |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | - |
| Amy Ladd | M | 66 | 2 jaar | |
| Peter Tontonoz | M | - |
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri with additional offices in San Diego and Cleveland. | 6 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Christopher Bebbington | M | - | 6 jaar | |
| Philip Needleman | M | - |
Pharmacia Corp.
 Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ.
G.D. Searle LLC
Kalypsys, Inc.
 Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA. | 7 jaar |
| Robert J. de Vaere | M | 66 |
IDM Pharma, Inc.
 IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | 4 jaar |
| Sanford J. Grossman | M | - |
The University of Chicago
| 6 jaar |
| Timothy Walbert | M | 57 |
IDM Pharma, Inc.
IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | 2 jaar |
| Geri Sands Hansen | F | - |
The University of Chicago
| 4 jaar |
| Eric Loumeau | M | 61 | 3 jaar | |
| Todd Eugene Petzel | M | - |
The University of Chicago
| 7 jaar |
| David A. Weber | M | 64 | 13 jaar | |
| George K. Hersh | M | - |
The University of Chicago
| 6 jaar |
| Robert J. Fanella | M | 73 |
The University of Chicago
Northern Illinois University
| 7 jaar |
| Barry Granger | M | 64 | 29 jaar | |
| Kai Kuo Chao | M | - |
The University of Chicago
| 3 jaar |
| Barbara Mazur | F | 74 |
The University of Chicago
| 4 jaar |
| Mauricio Antonio González Gómez | M | - |
The University of Chicago
| 3 jaar |
| Manuel Iglesias | M | 69 |
The University of Chicago
| 6 jaar |
| Nenad Tomasevic | M | - | 3 jaar | |
| Stu J. Sweet | M | - |
The University of Chicago
| 6 jaar |
| Julie Burgess | F | - | 7 jaar | |
| Peter Bisgaard | M | 50 | 5 jaar | |
| Chau Khuong | M | 48 | 3 jaar | |
| Stewart A. Noble | M | - |
Kalypsys, Inc.
Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA. | - |
| Pratik Shah | M | 54 |
Kalypsys, Inc.
Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA. | - |
| Gary K. Kilberg | M | - |
The University of Chicago
| 6 jaar |
| George Morrow | M | 72 | 3 jaar | |
| Heather Elizabeth Preston | M | 58 | 10 jaar | |
| Marc R. Reinganum | M | - |
The University of Chicago
| 5 jaar |
| Victor Canto | M | - |
The University of Chicago
| 5 jaar |
| Thomas James Czech | M | - |
Northern Illinois University
| 5 jaar |
| T. Eric Kilcollin | M | - |
The University of Chicago
| 5 jaar |
| James Ernest Catlin | M | 77 |
Northern Illinois University
| 5 jaar |
| Vickie Capps | F | 62 | 9 jaar | |
| Charles Frederick Pohl | M | - |
The University of Chicago
| 5 jaar |
| Michael Anthony Duffy | M | - |
The University of Chicago
| 8 jaar |
| Fred Hassan | M | 78 |
Pharmacia Corp.
Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | 3 jaar |
| Dennis Joseph McNamara | M | 70 |
The University of Chicago
| 7 jaar |
| Carla da Luz Boren | F | - | 6 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigde Staten | 100 | 100.00% |
| Zwitserland | 0 | -.--% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- John McKearn
- Persoonlijk netwerk
